ClearPoint Neuro, Inc. (CLPT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$13.96-0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Achieve 2026 revenue between $52M and $56M: FY26 rev guide $48M-$52M vs $52M-$56M target.
ClearPoint aims for $52M to $56M revenue in 2026. Revenue grew 26% in 2025. The company is working to improve its losses and cash flow. Recent pullback is a mild market correction.
ClearPoint keeps losing money and cash flow is worsening. Revenue guidance was cut. The company missed earnings several times recently.
The market expects about 36% revenue growth next year. Our fair value is near $6, reflecting some optimism but risks remain.
Breaks if: Cash flow worsens beyond -$7.97M over next 4 quarters
Breaks if: Operating loss worsens beyond -$8.48M over next 4 quarters
Revenue falls below $52M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation. CLPT has been struggling with losses and weak financial performance, but it operates in a sector that has favorable conditions, which could support its recovery over the long term.
The market seems to have priced in a cautious outlook, reflected in a justified valuation despite the company's losses. There is an expectations gap indicating that the market may anticipate continued challenges ahead.
Management is focused on achieving revenue guidance and expanding partnerships, but recent results have been weak with a high probability of missing future earnings. The company's financial trajectory is uncertain, given its history of consecutive earnings misses.
The long-term thesis hinges on management's ability to meet revenue targets and successfully integrate recent acquisitions. Additionally, broader sector performance and economic conditions, such as job growth, will significantly impact CLPT's prospects.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss is a key driver. This miss impacts confidence in the company's future performance. The overall market is also experiencing a risk-off sentiment.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, CLPT's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.